RxDoctor Payments Data

Peter Levinson, MD

Internal Medicine · Middlebury, CTNPI 1881612851

Payments from drug & device makers

$9,760in general payments, 2019–2025

Across 517 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Bayer$844
  • GSK$675
  • AstraZeneca$641
  • Boehringer Ingelheim$595
  • plus $5K from 40 others

What the payments were for

  • Speaking & faculty fees$120%
  • Food & beverage$9,55498%
  • Education$1351%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,760 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$78,088
Medicare patients
193
Services billed
1,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$76,421
JardianceEmpagliflozin36$53,677
JanuviaSitagliptin Phosphate33$52,503
OzempicSemaglutide42$43,765
JanumetSitagliptin Phos/Metformin Hcl35$34,061
XareltoRivaroxaban25$25,571
RybelsusSemaglutide15$22,805
Breo ElliptaFluticasone/Vilanterol32$15,077
Levothyroxine Sodium304$6,311
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,754
SynthroidLevothyroxine Sodium49$4,186
Dexlansoprazole DrDexlansoprazole11$4,037
Atorvastatin Calcium445$3,980
Omeprazole228$3,794
NexiumEsomeprazole Magnesium13$3,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$267$86,56468 claims
PfizerEliquis$376$76,42164 claims
Novo NordiskOzempic, Rybelsus$1,104$66,57057 claims
Boehringer IngelheimJardiance$595$53,67736 claims
Johnson & JohnsonXarelto$144$25,57125 claims
GSKBreo Ellipta$675$15,07732 claims
AbbVieSynthroid$1,307$4,18649 claims
AstraZenecaNexium$641$3,51813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →